ECSP10010632A - Conjugados del factor ix con vidas medias extendidas - Google Patents

Conjugados del factor ix con vidas medias extendidas

Info

Publication number
ECSP10010632A
ECSP10010632A EC2010010632A ECSP10010632A ECSP10010632A EC SP10010632 A ECSP10010632 A EC SP10010632A EC 2010010632 A EC2010010632 A EC 2010010632A EC SP10010632 A ECSP10010632 A EC SP10010632A EC SP10010632 A ECSP10010632 A EC SP10010632A
Authority
EC
Ecuador
Prior art keywords
factor
conjugates
lives
extended medium
extended
Prior art date
Application number
EC2010010632A
Other languages
English (en)
Inventor
William Henry
Original Assignee
Celtic Pharma Peg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtic Pharma Peg Ltd filed Critical Celtic Pharma Peg Ltd
Publication of ECSP10010632A publication Critical patent/ECSP10010632A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Resumen La presente invención se refiere a conjugados del Factor IX que han sido modificados para incluir una porción del polímero biocompatible. Los conjugados del Factor IX están sustancialmente libres de contaminación por el Factor IXa. Los conjugados del Factor IX tienen propiedades farmacocinéticas mejoradas, tales como vida media incrementada, lo cual da como resultado dosis moderada y administración menos frecuente.
EC2010010632A 2008-04-24 2010-11-24 Conjugados del factor ix con vidas medias extendidas ECSP10010632A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24

Publications (1)

Publication Number Publication Date
ECSP10010632A true ECSP10010632A (es) 2011-02-28

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010632A ECSP10010632A (es) 2008-04-24 2010-11-24 Conjugados del factor ix con vidas medias extendidas

Country Status (22)

Country Link
US (1) US20110183906A1 (es)
EP (1) EP2280734B1 (es)
JP (1) JP2011519833A (es)
KR (1) KR20110016440A (es)
CN (1) CN102046205A (es)
AU (1) AU2009239641B2 (es)
BR (1) BRPI0911350A2 (es)
CA (1) CA2722169A1 (es)
CO (1) CO6300965A2 (es)
CR (1) CR11763A (es)
DK (1) DK2280734T3 (es)
EC (1) ECSP10010632A (es)
ES (1) ES2466340T3 (es)
IL (1) IL208908A0 (es)
MX (1) MX2010011672A (es)
MY (1) MY158228A (es)
NI (1) NI201000177A (es)
NZ (1) NZ588854A (es)
RU (1) RU2496521C2 (es)
UA (1) UA101497C2 (es)
WO (1) WO2009130602A2 (es)
ZA (1) ZA201007559B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
PT3552619T (pt) * 2010-07-09 2025-10-23 Bioverativ Therapeutics Inc Polipéptidos de fator ix e métodos de uso dos mesmos
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
EP2714093A1 (en) * 2011-05-27 2014-04-09 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
GB201910190D0 (en) * 2012-04-16 2019-08-28 Cantab Biopharmaceuticals Patents Ltd Optimised subsutaneous therapeutic agents
SG11201407600UA (en) * 2012-06-19 2014-12-30 Polytherics Ltd Novel process for preparation of antibody conjugates and novel antibody conjugates
TWI810729B (zh) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
EP1982732A3 (en) * 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
JP4490290B2 (ja) * 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
WO2004060966A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
AU2004204136B2 (en) * 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PT2380985E (pt) 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
DK2189523T3 (da) 2003-10-14 2012-03-12 Baxter Int VKORC1 (vitamin K-epoxid-tilbageføringspolypeptid), et terapeutisk mål for coumarin og dets derivater
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
CA2590284A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
PT1853700E (pt) 2005-02-28 2013-01-14 Baxter Int Co-expressão recombinante da subunidade 1 da vitamina k epóxido redutase para melhorar a expressão de proteína dependente de vitamina
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US20090252720A1 (en) * 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病ｂ治療剤及びその製造方法

Also Published As

Publication number Publication date
MY158228A (en) 2016-09-15
IL208908A0 (en) 2011-01-31
JP2011519833A (ja) 2011-07-14
CN102046205A (zh) 2011-05-04
CA2722169A1 (en) 2009-10-29
DK2280734T3 (da) 2014-05-26
HK1151986A1 (en) 2012-02-17
AU2009239641A1 (en) 2009-10-29
BRPI0911350A2 (pt) 2017-12-05
US20110183906A1 (en) 2011-07-28
WO2009130602A3 (en) 2010-02-11
WO2009130602A9 (en) 2010-04-22
WO2009130602A2 (en) 2009-10-29
RU2010147813A (ru) 2012-05-27
EP2280734B1 (en) 2014-02-26
CO6300965A2 (es) 2011-07-21
RU2496521C2 (ru) 2013-10-27
CR11763A (es) 2011-04-26
KR20110016440A (ko) 2011-02-17
NZ588854A (en) 2011-12-22
NI201000177A (es) 2011-08-29
UA101497C2 (ru) 2013-04-10
EP2280734A2 (en) 2011-02-09
ES2466340T3 (es) 2014-06-10
ZA201007559B (en) 2012-01-25
AU2009239641B2 (en) 2013-11-07
MX2010011672A (es) 2011-03-02

Similar Documents

Publication Publication Date Title
CO6300965A2 (es) Conjugados de polimeros biocompatibles del factor ix, composiciones que comprenden conjugados del factor ix y, metodos de tratamiento
CY1124481T1 (el) Σταθερα χωρις συντηρητικα μυδριατικα και αντιοξειδωτικα διαλυματα για εγχυση
CR11737A (es) Polipéptidos modificados del factor ix y usos de los mismos
CL2015003580A1 (es) Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
BR122020010601B8 (pt) conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
UY31785A1 (es) Sistema polimerico de lagrimas artificiales
MX2018013333A (es) Composiciones de nucleasas terapeuticas y metodos.
ECSP13013097A (es) Coagonistas del receptor de glucagón/glp-1
CL2012001094A1 (es) Una silla que posee una sección base con uno o mas elementos de patas, una sección de asiento, un primer y segundo mecanismo para proporcionar un movimiento de rotación y un movimiento de deslizamiento lateral respectivamente al asiento, donde ambos mecanismos se activan de manera independiente del el estado de activación del otro.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
MX2021015735A (es) Composiciones de nucleasa terapeuticas y metodos.
FI20116138A7 (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
MX361155B (es) Cocleatos hechos con fosfatidilserina de soja.
MX341778B (es) Goma de mascar natural incluyendo materiales de celulosa.
BR112015008954A2 (pt) composições de ciclodextrina alquilatada e processos para preparação e uso das mesmas
BR112015009603A2 (pt) novos derivados de pirazina
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
MX2018003685A (es) Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.
BRPI1011630B8 (pt) paracetamol para a administração parenteral
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona